Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.

Published on Oct 1, 2017
· DOI :10.2147/ITT.S126227
Jennifer M Yoest1
Estimated H-index: 1
  • References (0)
  • Citations (15)
📖 Papers frequently viewed together
1 Author (Sharma R)
2 Citations
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By15
#1Nikhila Kethireddy (UConn: University of Connecticut)
#2Steffi Thomas (UConn: University of Connecticut)
Last. Upendra P. Hegde (UConn: University of Connecticut)H-Index: 14
view all 5 authors...
INTRODUCTION: Immune agents including anti-programmed death receptor-1 and anti-cytotoxic T-lymphocyte antigen-4 have been associated with numerous immune-related complications. Pembrolizumab, a programmed death-1 inhibitor, has been associated with a number of immune-related adverse events such as pneumonitis, colitis, hepatitis, hypophysitis, hyperthyroidism, hypothyroidism, nephritis, and type 1 diabetes. CASE REPORT: We present a rare case of an elderly male on pembrolizumab who suffered fro...
#1Manuel Ramos-Casals (University of Barcelona)H-Index: 63
#2Julie R. Brahmer (Johns Hopkins University)H-Index: 58
Last. Maria E. Suarez-Almazor (University of Texas MD Anderson Cancer Center)H-Index: 66
view all 10 authors...
Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have a delayed onset and prolonged duration. IrAEs can involve any organ or sy...
#1Rhiane Moody (RMIT: RMIT University)
#2Kirsty L. Wilson (RMIT: RMIT University)H-Index: 1
Last. Magdalena Plebanski (RMIT: RMIT University)H-Index: 47
view all 4 authors...
Cancer-related deaths are approaching 10 million each year. Survival statistics for some cancers, such as ovarian cancer, have remained unchanged for decades, with women diagnosed at stage III or IV having over 80% chance of a lethal cancer recurrence after standard first-line treatment (reductive surgery and chemotherapy). New treatments and adjunct therapies are needed. In ovarian cancer, as in other cancers, the immune response, particularly cytotoxic (CD8+) T cells are correlated with a decr...
#1Karen A. Autio (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 13
#2Valentina BoniH-Index: 10
Last. Aung Naing (University of Texas MD Anderson Cancer Center)H-Index: 41
view all 4 authors...
The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and other cancers. ICIs are under development across many tumor types and...
2 CitationsSource
Current response assessment systems for cancer patients receiving immunotherapy are limited. This is due to the associated inflammatory response that may confound the conventional morphological response evaluation criteria in solid tumors and metabolic positron emission tomography (PET) response criteria in solid. Recently, novel PET imaging techniques using radiolabeled antibodies and fragments have emerged as a particularly sensitive and specific modality for quantitative tracking of immune ce...
#1Satya Das (VUMC: Vanderbilt University Medical Center)H-Index: 3
#2Douglas B. Johnson (VUMC: Vanderbilt University Medical Center)H-Index: 40
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit from ICIs is a major research focus for the oncology community. Thus far, predictive biomarker research has focused on tumor signatures such as microsatellite instability, programmed death-ligand 1 (PD-L...
10 CitationsSource
#1Nora MöhnH-Index: 2
#2Gernot BeutelH-Index: 19
view all 6 authors...
Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated with a wide spectrum of immune-related adverse events (irAE) including neurological symptoms which can affect all parts of the central and peripheral nervous system. Even though these events are rare, they are of high relevance as the rate of residual symptoms or even fatal outcomes is remarkable. To provide a detaile...
4 CitationsSource
#1Steffi Thomas (UConn: University of Connecticut)
#2Chay Bae (UConn: University of Connecticut)
Last. William Traverse (UConn: University of Connecticut)
view all 4 authors...
IntroductionThe landscape for the treatment of metastatic melanoma has been revolutionized with the introduction immune checkpoint inhibitors. Immune checkpoint inhibitors have now become the stand...
#1Domenico Ribatti (University of Bari)H-Index: 82
#2Tiziana Annese (University of Bari)H-Index: 14
Last. Enrico Crivellato (University of Udine)H-Index: 39
view all 5 authors...
Abstract Clinical trials using anti-vascular endothelial growth factor /(VEGF) molecules induce a modest improvement in overall survival, measurable in weeks to just a few months, and tumors respond differently to these agents. In this review article, we have exposed some tumor characteristics and processes that may impair the effectiveness of anti-angiogenic approaches, including genotypic changes on endothelial cells, the vascular normalization phenomenon, and the vasculogenic mimicry. The usa...
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Antoninus Soosaipillai (MSH: Mount Sinai Hospital, Toronto)H-Index: 35
Last. Eleftherios P. DiamandisH-Index: 99
view all 6 authors...
Background Autoantibodies are produced when tolerance to self-antigens is broken and they can be mediators of tissue injury and systemic inflammation. They are excellent biomarkers because they are minimally invasive to screen and are highly abundant in serum due to limited proteolysis and slow clearance. Conventionally used methods of identifying autoantibodies in patient sera include indirect immunofluorescence, enzyme-linked immunoabsorbent assays (ELISAs) and protein microarrays. Here we pre...
1 CitationsSource